Kornimate/medical-research-clean huggingface dataset:
quantitative fluorescence endoscopy using durvalumab-680lt in esophageal cancer

Conditions: Esophageal Cancer

Summary: treatment of patients with locally advanced esophageal cancer (ec) is multidisciplinary and consists of neoadjuvant therapy followed by surgical removal of the esophageal tumor and potentially tumor positive lymph nodes. the beneficial effect of the addition of immunotherapy to improve response rates to current treatment strategies has been investigated response to, since only 16 to 43% of ec patients achieve a pathological complete response (pcr) after neoadjuvant therapy and a pcr is associated with better long-term outcomes. unfortunately, not all patients respond to immunotherapy and the knowledge about biomarkers that predict response to therapy are required. a promising novel parameter is tumor programmed death-ligand 1 (pd-l1) expression, one of the immune checkpoints targeted by cancer immunotherapy. studies performed in patients with various solid tumors demonstrate improved response to immunotherapy and survival benefit in patients with higher pd-l1 expression. nonetheless, not all patients with high pd-l1 expression show benefit and some without expression do. moreover, mostly biopsy-based tests are used to assess pd-l1 status, although these tests are prone to errors, partly due to heterogeneity in tissue expression. novel methods are needed to gain more insight in the pd-l1 expression in order to better select patients who are likely to benefit from immunotherapy. the investigators hypothesize that quantitative fluorescence endoscopy using the tracer durvalumab-680lt targeting pd-l1 is a promising technique to investigate the heterogeneity of pd-l1 expression.


Eligibility criteria:
inclusion criteria: * lesion suspected for locally advanced ec (ct1b-4a n0-3 m0) * indication for neoadjuvant therapy * age ≥ 18 years; * written informed consent. exclusion criteria: * medical or psychiatric conditions that compromise the patient's ability to give informed consent according to treating medical physician; * concurrent uncontrolled medical conditions according to treating medical physician; * medical history of auto-immune disease * pregnancy or breast feeding. a negative pregnancy test must be available for women of childbearing potential (i.e. premenopausal women with intact reproductive organs and women less than two years after menopause); * irradical endoscopic mucosal resection (emr) or endoscopic submucosal dissection (esd) of the primary tumor prior to start of neoadjuvant therapy according to the patient's medical history; * received an investigational drug within 30 days prior to the dose of durvalumab-680lt according to the patient's medical history; * history of infusion reactions to durvalumab or other monoclonal antibodies according to the patient's medical history;
behavioral activation for post-stroke sedentary behavior using telehealth

Conditions: Stroke; Stroke, Ischemic; Stroke Hemorrhagic

Summary: adults with stroke-related disability spend more time sedentary than adults without stroke-related disability, which places them at risk for poor cardiovascular health outcomes. few interventions are designed to reduce post-stroke sedentary time. the purpose of this research is to test whether the teleable (activating behavior for lasting engagement) intervention is feasible and acceptable to adults within the first 12 months post-stroke. the hypothesis is that teleable can be feasibly delivered using videoconferencing within the first 12 months post-stroke. 10 participants will complete assessments and activity monitoring (activpal micro3) at 0 (baseline) and 8 (post-intervention)-weeks. participants will complete 12 sessions of the teleable intervention. findings from this study will be used to guide the intervention protocol in the planned next phase of this research.


Eligibility criteria:
inclusion criteria: * stroke diagnosis ≤12 months prior to study enrollment * ≥6 hours of sedentary behavior on a typical weekday (assessed by sedentary behavior questionnaire) * ambulatory with or without assistive device (assessed by functional independence measure, mobility score ≥5) * able to access an electronic device (smartphone, tablet, or computer) that is compatible with a videoconferencing application * able to identify a support person with whom the participant has face-to-face interaction at least one time per week * able and willing to participate fully in the study and provide informed consent exclusion criteria: * currently receiving care in an inpatient rehabilitation, transitional care unit, or skilled nursing facility * severe cognitive or communication impairments (inability to respond accurately to complete study telephone screening or complete informed consent) * comorbid neurodegenerative disorder (e.g. parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, myasthenia gravis, dementia, alzheimer's disease, huntington's disease, glioblastoma) * comorbid cancer, currently undergoing chemotherapy or radiation treatment * comorbid major depressive disorder (assessed by patient health questionnaire-2, score ≥2) * received inpatient treatment or hospitalized for psychiatric condition and/or alcohol or substance abuse within the past 12 months * diagnosis of a terminal illness and/or in hospice care * history of skin sensitivity that precludes the use of medical tape necessary for adherence to activity monitor measure * inability to speak, read, or understand english * concurrent participation in another rehabilitation intervention research study * investigator discretion for safety or adherence reasons
a study of dimethyl fumarate (dmf) in relapsing forms of multiple sclerosis (rms) participants in china

Conditions: Multiple Sclerosis

Summary: the primary objective of the study is to assess the efficacy of dmf in chinese participants with rms at week 48. the secondary objectives of the study are to assess the efficacy and safety of dmf in chinese participants with rms.


Eligibility criteria:
key inclusion criteria: * must have a baseline (pre-dose on day 1) expanded disability status scale (edss) between 0.0 and 5.0, inclusive. * must have experienced at least 1 documented relapse within the 12 months before screening, with a prior brain magnetic resonance imaging (mri) demonstrating lesion(s) consistent with ms or have showed evidence of gde lesion(s) of the brain on an mri performed within the 6 weeks prior to screening. key exclusion criteria: * an ms relapse that occurred within the 30 days prior to screening and/or the participant has not stabilized from a previous relapse prior to screening. * current hepatitis c infection and current hepatitis b infection. participants with immunity to hepatitis b from previous natural infection or vaccination are eligible to participate in the study. * history of severe allergic or anaphylactic reactions or of any allergic reactions that, in the opinion of the investigator, are likely to be exacerbated by any component of the study treatment. * history or positive test result at screening for human immunodeficiency virus (hiv). * use at the time of enrollment and/or anticipated ongoing use of any traditional and/or unlicensed medicines and/or traditional therapies and/or herbal preparations, which are known or considered by the investigator to affect ms and endpoints that are being considered in the study, including safety and efficacy. * current enrollment in any other investigational drug study or participation in any other investigational study within 6 months prior to screening. note: other protocol defined inclusion/exclusion criteria may apply.
impact of cpap treatment on arterial stiffness in patients with t2dm and newly diagnosed obstructive sleep apnoea

Conditions: Diabetes; Obstructive Sleep Apnea

Summary: the purpose of the trial is to investigate the effects of three months' treatment with a cpap-device versus control group on change in arterial stiffness in type 2 diabetes (t2d) patients with newly detected obstructive sleep apnoea (osa).

background: obstructive sleep apnoea (osa) is a common disorder characterised by recurrent episodes of apnoea or hypopnoea during sleep. osa is associated with excessive daytime sleepiness and linked to increased cardiovascular morbidity and mortality. osa can be alleviated with continuous positive airway pressure (cpap) treatment. cardiovascular disease is the major cause of decreased life expectancy, morbidity and reduced quality of life in patients with type 2 diabetes (t2d). increased stiffness of the aorta has been associated with increased cardiovascular morbidity and mortality in diabetic patients. previous studies have reported a much higher frequency of osa in patients with obesity and t2d compared with non-diabetic subjects, and found that osa was associated with arterial stiffness. however, whether cpap treatment improves arterial stiffness and insulin sensitivity in t2d patients remain to be elucidated. objective: to investigate the effects of three months' treatment with a cpap-device versus sham cpap on change in arterial stiffness in t2d patients with newly detected osa. design: randomised, controlled, multicentre study of intervention with cpap treatment versus control group. the treatment period is three months with a subsequent 9 months open extension. patient population: 70 patients with t2d and newly diagnosed osa recruited from department of cardiology, nephrology and endocrinology, nordsjællands hospital, department of endocrinology, gentofte university hospital, department of endocrinology and internal medicine, aarhus university hospital nørrebrogade and department of internal medicine, silkeborg sygehus. intervention: cpap treatment versus control group. endpoints: primary endpoint: change in arterial stiffness measured by office carotid-femoral pulse wave velocity (cf-pwv) from start to end of 12 weeks intervention.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus (who criteria) * obstructive sleep apnea defined as apnoea-hypopnoea index (ahi) \> 15 diagnosed with apnealink+® measured within three months or less prior to visit 0. * signed informed content. exclusion criteria: * contraindications to cpap treatment. * treatment with cpap within the last 6 months prior to visit 1. * works in a transportation-related industry * c-peptide \< 300 pmol/l - measured less than 6 months prior to visit 0 * hba1c:\ 10% - both exclusive - at visit 0 * changes in antidiabetic treatment during the last four weeks prior to visit 0. * unstable bodyweight, i.e. \>5% change during the last three months prior to visit 0. * other sleep breathing disorder
correlation of arterial blood gas (abg) and venous blood gas (vbg) in the undifferentiated critically ill patient

Conditions: Patients Needing Blood Gases

Summary: the primary objective of this study is to identify a correlation between the ph and pco2 in arterial and venous blood. the secondary objectives include a correlation of pulse oximetry and arterial po2 along with subgroup analyses of specific patient populations such as congestive heart failure, chronic obstructive pulmonary disease, diabetic ketoacidosis, pneumonia, overdose, and trauma.


Eligibility criteria:
inclusion criteria: * age 18 years or older signed consent patient in the ed or icu have a disease state that necessitates obtaining an abg have a disease state that necessitates pulse oximetry monitoring exclusion criteria: * any contraindication to arterial or venous blood draw prior enrollment in the study during the current hospitalization pregnancy prisoners

Keywords: abg vbg ph pco2
partial breast irradiation with multi-catheter brachytherapy for pt1-2pn0 breast cancer after breast conserving surgery

Conditions: Breast Cancer

Summary: the purpose of this study is to determine whether accelerated partial breast irradiation (apbi) with multi-catheter brachytherapy is safe and effective.


Eligibility criteria:
inclusion criteria: * pt1/2 (≤ 3 cm) * pn0 or pn1 mi * m0 and no contralateral bc * clear margins (≥ 2 mm) * age ≥ 35 years * er and/or pr positive exclusion criteria: * multifocality or multicentricity * eic * lymphovascular invasion * poorly differentiated tumors * diffuse microcalcifications

Keywords: accelerated partial breast irradiation multicatheter brachytherapy high dose rate brachytherapy pulsed dose rate brachytherapy
training of eye movements in glaucoma

Conditions: Glaucoma; Eye Yoga

Summary: the aim of the trial is to investigate the possibilities of improving visual impairments with eye training exercises (eye-yoga) in a total of 40 patients with glaucoma who have not previously been treated within a similar training program. 20 patients will be instructed how to do eye yoga to be performed dails for 4 weeks (max 30 min/day). as a control group of 20 patients will be instructed to read for 30 min/day for 4 weeks. the following outcome measures will be investigated: high resolution perimetry, humphrey perimetry, visual acuity test, contrast sensitivity test, microsaccades measurements, intraocular pressure measurement, electroencephalogram (eeg), blood pressure and pulse measurement and dynamic vessel analysis (dva - the blood supply in the eye (especially vascular dysregulation) . furthermore, factors that could influence response variability and the effectiveness of treatment will be analysed: (i) the role of mental stress (or stress resilience) and (ii) the influence of personality traits and quality of life. the study is intended to further validate this home training program (eye yoga) for the treatment of visual impairment in glaucoma.

the aim of eye yoga is to improve microsaccade impairments in patient with primary open angle glaucoma. we will study how this affects visual performance and the physiology of the eye and brain

Eligibility criteria:
inclusion criteria: * clinical diagnosis of glaucoma * residual vision * the duration of the disease must be at least 6 months old * the visual field defect must be stable exclusion criteria: * autoimmune diseases in the acute stage * neurological and mental diseases * diabetic retinopathy * addictions * hypertension (maximum 160/100 mmhg) * retinitis pigmentosa- * pathological nystagmus * non-distant tumors or recurrent tumors * photosensitivity * pregnancy
efficacy and safety of varenicline in smokers with cardiovascular disease who wish to quit smoking

Conditions: Smoking Cessation

Summary: the primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.


Eligibility criteria:
inclusion criteria: * participants must have stable, documented cardiovascular disease (including at least one of the following diagnosed \> 2 months prior to the screening visit - angina, myocardial infarction (mi), revascularization, transient ischemic attack (tia), and peripheral vascular disease (pvd). * participants that smoke \> 10 cigarettes / day. exclusion criteria: * participants with unstable cardiovascular disease * cardiovascular events in the past 2 months * moderate or severe chronic obstructive pulmonary disease (copd)
efficacy of trans-spinal magnetic stimulation on functional mobility in chronic stroke patients

Conditions: Stroke Sequelae; Gait Disorders, Neurologic; Stroke

Summary: the goal of this clinical trial is to learn if trans-spinal magnetic stimulation works to treat gait disorders in chronic stroke adults. it will also learn about the safety of trans-spinal magnetic stimulation. the main questions it aims to answer are: does trans-spinal magnetic stimulation enhance chronic stroke participants gait and functional mobility? does the technique cause any side effects? researchers will compare trans-spinal magnetic stimulation to a sham (a look-alike stimulation with no real effect) to see if trans-spinal magnetic stimulation works to treat gait disorders and improve functional mobility. participants will: receive trans-spinal magnetic stimulation with treadmill training or a sham stimulation with treadmill training every day for 2 weeks.


Eligibility criteria:
inclusion criteria: * confirmation of stroke by digital or physical imaging or medical report * gait impairment * stroke with at least 6 months after ictus exclusion criteria: * metallic implants in spinal cord * major orthopedic/rheumatological disorders * incapacity of verbal or non-verbal communication

Keywords: spinal cord magnetic stimulation trans-spinal magnetic stimulation stroke
observatory children acute related therapy leukemia

Conditions: Leukemia, Myeloid, Acute

Summary: acute myeloid leukemias (aml) of the child are a rare disease and its prognosis varies according to the subgroup. secondary amls remain a subgroup of poor prognosis, whose cytogenetic and molecular characteristics and prognostic value differ in part from de novo amls. the purpose of this national observatory is to record scientific and medical information on cases of secondary aml that have occurred in france since 2013 in order to improve the treatment of children and adolescents with this disease in the years to come. this national observatory will contribute to better knowledge and progress in research into these diseases.

therapy-related myeloid neoplasms (t-mns) are a group of hematologic diseases that arise after chemotherapy and/or radiation therapy for a previous cancer or rarely autoimmune diseases. t-mns had been included in the group of amls and remain as a distinct category also in the recent 2016 revision of the who classification of myeloid neoplasm and acute leukemia. the latency between exposition to anticancer drugs and development of t-mn may vary from some months up to 10 years, even considering the age at diagnosis of the primary malignancy, the kind of cytotoxic treatment previously used, and the cumulative dose and dose intensity. the prognosis of s-aml is generally considered to be poorer than that of de novo aml. the disease tends to be refractory to chemotherapy, and patients' tolerance of treatment generally is reduced because of prior therapies. 5-year event-free survival (efs) and overall survival (os) rates of pediatric t-aml/t-mds have been reported to be 14% to 30%. however, the results are conflicting and overall lacking when compared with those in adults. the purpose of this national observatory is to record scientific and medical information on cases of secondary acute myeloid leukemias that have occurred in france since 2013 in order to improve the treatment of children and adolescents with this disease in the years to come. the primary objective is to evaluate the association of potential prognostic factors (including clinical-biological factors) with the overall survival of children and adolescents aged 0-18 years diagnosed with secondary aml. the secondary objectives are to test the feasibility of setting up a french national database of secondary amls for children and adolescents as a first step towards european implementation, to assess the association of potential prognostic factors with event free survival and the occurrence of treatment-related toxicities, to characterize the molecular abnormalities associated with secondary amls in children and adolescents.

Eligibility criteria:
inclusion criteria: * patients aged 0-18 years * patient with first cancer * diagnosis of secondary aml * patients treated in a sfce (société française des cancers de l'enfant) center * for cases included in the prospective from march 2019 onwards: consent of holders of parental authority and consent of the child of understanding age exclusion criteria: none

Keywords: secondary acute myeloid leukemia children
short-term effects of tai chi chuan exercise on the regulation of lipid and glucose metabolisms and endothelial function

Conditions: Physiological Effect of TCC on Glucose Metabolism

Summary: the short term effects of tcc exercise are the significant increase in serum insulin and insulin resistance, and the significant decrease in serum tc, hdl-c, et-1 and insulin sensitivity in tcc practitioners. tcc might be benefit the health of its practitioners through the regulation of lipid and glucose metabolism and endothelial function.

tai chi chuan (tcc) has been shown to be beneficial to the health. however, its effects on lipid and glucose metabolism are not fully understood. this study investigated the short term effect of tcc exercise on lipid and glucose metabolism and endothelial function in tcc practitioners. twenty-one tcc practitioners and nineteen normal controls were included in this study. the hemodynamics, serum insulin, indices of insulin resistance/sensitivity, serum endothelin-1 (et-1), blood lipids and aldosterone before and 30 min after a rest or a session of classical yang's tcc exercise were compared.

Eligibility criteria:
inclusion criteria: * tcc practitioners in a tcc training center in taiwan over 50 years of age * healthy subjects without tcc experience over 50 years of age exclusion criteria: * subjects who had major cardiopulmonary disease * subjects who have diabetes mellitus, renal or liver disease

Keywords: tai chi chuan insulin resistance cholesterol endothelin-1
chongqing diabetes registry study

Conditions: Diabetes Mellitus

Summary: to investigate the risk factors and biomarkers of the microvascular disease，macrovascular disease and neuropathy in patients with diabetes.

this study is a prospective cohort study. about 5000 patients with diabetes from the chongqing diabetes centre,chongqing,china, will be enrolled for long-term follow-up.information on socio-demographic parameters, medical history, current drug use,lifestyle factors, anthropometric measurements, metabolic control indicators and diabetes complications examination will be documented. blood and urine samples will be collected. this study aimed to assess risk factors and biomarkers of occurrence and development of diabetic microvascular disease,macrovascular disease and neuropathy in patients with diabetes.

Eligibility criteria:
inclusion criteria: 1. diagnosis of diabetes mellitus（based on the 1999 who diagnostic cretirial）; 2. age younger than 75 years old, gender is not limited; 3. voluntary to sign on the informed consent. exclusion criteria: 1. pregnant or breast-feeding women; 2. patients with chronic disease requiring long-term glucocorticoid therapy; 3. patients with severe infection (except for diabetic foot) or immune dysfunction.

Keywords: diabetes mellitus risk factors biomarkers chronic diabetes complications
cumulative live birth rates in dual ovarian stimulation versus two antagonist stimulations in poor ovarian responders

Conditions: Infertility

Summary: to compare the difference in cumulative live birth rates between dual ovarian stimulation and two antagonist stimulations in poor ovarian responders.

studies have shown the ability to obtain oocytes with equivalent quality from the follicular and the luteal phase, and a higher number of oocytes within one cycle when using dual ovarian stimulation (duostim). this could be particularly relevant for women with poor ovarian responders (por). whether the cumulative live birth rates differ after duostim and two antagonist stimulations in por remains controversial.

Eligibility criteria:
inclusion criteria: * women with por were defined with adjusted bologna criteria, at least two of the three following criteria: advanced maternal age (40 years); 3 oocytes in previous ivf; and antral follicle count (afc) 5 and/or anti-mu¨llerian hormone (amh) 1.1 ng/ml (this criterion was mandatory) * aged from 20 to 44 years * body mass index (bmi) from 19 to 32 kg/m2 * no more than two previous ivf cycles were recruited exclusion criteria: * amenorrhoea * follicle stimulating hormone (fsh) 20 iu/l or afc 1 * women with a partner with an extremely severe sperm anomaly or sperm donor use